Premium
Transient symptomatic worsening by atropine in opsoclonus–myoclonus syndrome
Author(s) -
Miyoshi Hirotsugu,
Nakamura Ryuji,
Yamaga Ayano,
Haraki Toshiaki,
Yasuda Toshimichi,
Hamada Hiroshi,
Kawamoto Masashi
Publication year - 2017
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1111/ped.13180
Subject(s) - medicine , atropine , myoclonus , midazolam , anesthesia , sedation , neuroscience , psychology
Opsoclonus–myoclonus syndrome ( OMS ) is characterized by abnormal eye and systemic involuntary movements, as well as cerebellar ataxia. Some sedatives and anesthetics worsen movements associated with OMS , while there is no known report of a negative effect of atropine. We report on sedation in two patients with OMS . Involuntary movements were transiently worsened after using atropine with midazolam or thiamylal in both, but were not seen when atropine was not used. We speculated that atropine has the potential to exacerbate involuntary movements in OMS due to vulnerability to this agent via unknown mechanisms.